Literature DB >> 25058998

Advantages of minimal incision laparoscopic cholecystectomy.

Nasser Sakran, David Goitein, Asnat Raziel, Dan Hershko, Amir Szold.   

Abstract

BACKGROUND: Modifications to conventional laparoscopic cholecystectomy (CLC) are aimed at decreasing abdominal wall trauma and improving cosmetic outcome. Although single-incision laparoscopic surgery (SILS) provides excellent cosmetic results, the procedure is technically challenging and expensive compared to the conventional laparoscopic approach.
OBJECTIVES: To describe a novel, hybrid technique combining SILS and conventional laparoscopy using minimal abdominal wall incisions.
METHODS: Fifty patients diagnosed with symptomatic cholelithiasis were operated using two reusable 5 mm trocars inserted through a single 15 mm umbilical incision and a single 2-3 mm epigastric port. This technique was clubbed "minimal incision laparoscopic cholecystectomy" (MILC).
RESULTS: MILC was completed in 49 patients (98%). In five patients an additional 3 mm trocar was used and in 2 patients the epigastric trocar was switched to a 5 mmtrocar. The procedure was converted to CLC in one patient. Mean operative time was 29 minutes (range 18-60) and the average postoperative hospital stay was 22 hours (range 6-50). There were no postoperative complications and the cosmetic results were rated excellent by the patients.
CONCLUSIONS: MILC is an intuitive, easy-to-learn and reproducible technique and requires small changes from CLC. As such, MILC may be an attractive alternative, avoiding the cost and complexity drawbacks associated with SILS.

Entities:  

Mesh:

Year:  2014        PMID: 25058998

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  1 in total

1.  Is the fourth port routinely required for laparoscopic cholecystectomy? Our three-port laparoscopic cholecystectomy experience.

Authors:  A Ciftci; M B Yazicioglu; C Tiryaki; H T Turgut; O Subasi; M Ilgoz; O Civil; S Y Yildiz
Journal:  Ir J Med Sci       Date:  2016-08-31       Impact factor: 1.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.